Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. (SANA) is a leading developer of engineered cell therapies targeting complex diseases through innovative gene editing and immune evasion technologies. This resource provides centralized access to official press releases, clinical trial milestones, and strategic updates from the company.
Investors and industry observers will find timely updates on SANA's hypoimmune (HIP) platform progress, allogeneic CAR T-cell therapy developments, and advancements in diabetes/autoimmune disease research. The curated news collection includes regulatory filings, partnership announcements, and financial results essential for tracking this biotechnology innovator.
Key content categories include clinical trial phases, scientific publications, manufacturing expansions, and intellectual property developments. All materials are sourced directly from company disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined monitoring of SANA's progress in creating off-the-shelf cellular medicines. Check back regularly for verified updates on their pipeline targeting oncology, diabetes, and central nervous system disorders.
Sana Biotechnology (NASDAQ: SANA) will webcast presentations at two investor conferences in December 2025 featuring a business overview and update by Steve Harr, President and CEO.
Sana will present at Citi’s 2025 Global Healthcare Conference on Dec 2, 2025 at 2:30 p.m. ET and at the 8th Annual Evercore Healthcare Conference on Dec 3, 2025 at 2:35 p.m. ET. Live webcasts and replays will be available on Sana’s Investor Relations page at https://sana.com/, with each replay accessible for 30 days after the conference.
Sana Biotechnology (NASDAQ: SANA) reported Q3 2025 results and strategic reprioritization focused on SC451 (HIP-modified iPSC-derived islet cells for type 1 diabetes) and SG293 (next‑generation in vivo CAR T).
Key developments: NEJM published positive 12-week data for UP421 showing transplanted HIP-modified islet cells survived, evaded immune detection, and produced C-peptide without immunosuppression. Sana expects to file an IND for SC451 as early as 2026 and an IND for SG293 as early as 2027. The company suspended enrollment and internal investment in its allogeneic CAR T programs SC291 and SC262 to focus resources.
Financials: Cash $153.1M at Sept 30, 2025; raised additional equity in Q3–Q4 2025 and expects a cash runway into late 2026. Non-cash impairment of $44.6M recorded in 2025.
Sana Biotechnology (NASDAQ: SANA) will present at the TD Cowen Immunology & Inflammation Summit on Wednesday, November 12, 2025 at 1:30 p.m. ET. The presentation, given by Steve Harr, President and CEO, will provide a business overview and company update.
The presentation will be webcast and available on Sana's Investor Relations website at https://sana.com/. A replay will be posted at the same location for 30 days after the conference.
Sana Biotechnology (NASDAQ: SANA), a company specializing in engineered cell therapies, has announced its participation in four major investor conferences this September 2025.
The company will present business overviews and updates at:
- Citi's Biopharma Back-to-School Conference on September 2 at 3:15 PM ET
- Wells Fargo Healthcare Conference on September 4 at 8:00 AM ET
- Morgan Stanley Global Healthcare Conference on September 8 at 11:30 AM ET
- HC Wainwright Global Investment Conference on September 9 at 9:30 AM ET
All presentations will be available via webcast on Sana's Investor Relations website, with replays accessible for 30 days after each event.
Sana Biotechnology (NASDAQ: SANA) has successfully closed the full exercise of underwriters' option to purchase additional shares, following its previously announced public offering. The company sold 3,358,208 shares at $3.35 per share, generating total gross proceeds of approximately $86.3 million including the main offering.
The offering was managed by joint book-runners Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen. The transaction was conducted under a previously filed and SEC-approved Registration Statement on Form S-3.
Sana Biotechnology (NASDAQ: SANA) reported significant progress in Q2 2025, highlighted by positive 6-month clinical results for their type 1 diabetes treatment using hypoimmune-modified pancreatic islet cells. The study, published in the New England Journal of Medicine, demonstrated successful cell transplantation without immunosuppression.
The company strengthened its financial position by raising $105 million through ATM offerings and equity financing in July-August 2025. Q2 ended with $72.7 million in cash, with a pro forma position of $177.2 million. The company expects its cash runway to extend into H2 2026.
Key pipeline developments include plans to file INDs for SC451 and SG299 in 2026, ongoing enrollment in the GLEAM trial (SC291) for autoimmune diseases and VIVID trial (SC262) for B-cell malignancies, with clinical data expected in 2025.
Harbinger Health announced the appointment of Ajit Singh, Ph.D. as its new CEO and CEO-Partner of Flagship Pioneering. Singh, who has served on Harbinger's board since 2024, brings extensive diagnostics industry experience, particularly from his tenure at Siemens and leadership in oncology diagnostics companies.
Current CEO Stephen Hahn, M.D. will transition to CEO Emeritus and Special Advisor while maintaining his position on the Board of Directors. The leadership change comes as Harbinger advances its platform for early cancer detection using blood-based tests that analyze proprietary methylation patterns of cell-free ctDNA.
The company recently presented data showing promising results in detecting multiple high-incidence, high-mortality cancers related to obesity, along with platform innovations to enhance cancer signal detection.
Sana Biotechnology (NASDAQ: SANA) has announced the pricing of its public offering, consisting of 20,895,522 shares of common stock at $3.35 per share and pre-funded warrants to purchase 1,492,537 shares at $3.3499 per warrant. The company expects to raise approximately $75.0 million in gross proceeds before deducting expenses.
The offering includes a 30-day option for underwriters to purchase up to 3,358,208 additional shares. Morgan Stanley, Goldman Sachs, BofA Securities, and TD Cowen are serving as joint book-running managers. The offering is expected to close around August 8, 2025, subject to customary conditions.
Sana Biotechnology (Nasdaq: SANA), a company specializing in engineered cells, has announced a proposed public offering of $75.0 million in common stock and pre-funded warrants. The company will also grant underwriters a 30-day option to purchase up to an additional $11.25 million of common stock.
The offering will be managed by joint book-running managers Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen. The offering will be made through a Registration Statement on Form S-3 previously filed with the SEC.
Sana Biotechnology (NASDAQ: SANA) has achieved a groundbreaking milestone in treating Type 1 diabetes, as published in the New England Journal of Medicine. The company successfully transplanted hypoimmune (HIP)-modified pancreatic islet cells in a 42-year-old patient with type 1 diabetes, marking the first successful transplantation without immunosuppression.
The study demonstrated that the transplanted cells survived, evaded immune detection, and produced insulin over a 12-week period, with additional positive data at 6 months. The patient, who had lived with diabetes for over three decades, showed measurable insulin production for the first time in 35 years.
Building on these results, Sana is developing SC451, a HIP-modified, stem cell-derived therapy, with plans to file an IND application as early as 2026. The company aims to provide a one-time treatment for type 1 diabetes patients that enables normal blood glucose levels without requiring insulin or immunosuppression.
FAQ
What is the current stock price of Sana Biotechnology (SANA)?
What is the market cap of Sana Biotechnology (SANA)?
